Most people with detectable virus at week four will be cured, according to Sreetha Sidarthan from the Institute of Human Virology in Baltimore and colleagues, who analyzed results from the ERADICATE and
SYNERGY trials of sofosbuvir-based regimens. Of the 17 people with detectable RNA at week 4 in SYNERGY, 100 percent were cured. In ERADICATE, 32 of 50 people had detectable HCV RNA at week 4; ultimately, 31 of the 32 were cured. EOT testing did not reliably predict cure either.